A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients

article by Mehrdokht Mazdeh et al published 8 April 2019 in Clinical and translational medicine

A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1113293242
P356DOI10.1186/S40169-019-0228-7
P932PMC publication ID6451934
P698PubMed publication ID30957197

P50authorSoudeh Ghafouri-FardQ38548826
Mohammad TaheriQ56246002
P2093author name stringMehrdokht Mazdeh
Shahriar Kargar Monhaser
P2860cites workCorrelation between brain volume loss and clinical and MRI outcomes in multiple sclerosisQ35116652
New management algorithms in multiple sclerosisQ38206631
Determination of cytokine levels in multiple sclerosis patients and their relevance with patients' response to Cinnovex.Q38731809
Heterogeneity in multiple sclerosis: scratching the surface of a complex disease.Q41295973
Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis TreatmentsQ47200732
The multiple sclerosis severity score (MSSS) predicts disease severity over timeQ83177562
The effectiveness of fingolimod in a Portuguese real-world populationQ89156361
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Q22252938
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosisQ26771635
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisQ28270998
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosisQ28271008
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialQ30789784
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosisQ34624835
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectfingolimodQ425137
relapsing-remitting multiple sclerosisQ18555066
P304page(s)11
P577publication date2019-04-08
P1433published inClinical and translational medicineQ27724586
P1476titleA non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients
P478volume8

Search more.